ENTITY
Alnylam Pharmaceuticals

Alnylam Pharmaceuticals (ALNY US)

66
Analysis
Health CareUnited States
Alnylam Pharmaceuticals Inc. is an early-stage therapeutics company. The Company is developing technology that can specifically and potently silence disease-causing genes.
more
Refresh
bullishS&P 500 INDEX
28 Nov 2019 06:30

U.S. Equity Strategy: Upgrading Health Care to Overweight

Ongoing bullish developments continue to support our belief that we are in the early stages of a broad-based advance following a nearly 2-year...

Logo
375 Views
Share
26 Jun 2018 15:55

Trade Risks Start to Impact, as China Biotech Ambitions Grow…

Cyclical indicators are softening this month - new orders index for the Philly Fed fell nearly 23 points while Japan’s PMI new export orders...

Logo
126 Views
Share
05 Jan 2018 09:35

Human Longevity

At KIS capital we try to keep ourselves at the forefront of technology and innovation, attempting to identify which industries may blossom, and...

Share
28 Nov 2017 16:52

Drugs Evolving Into 'Biological Software' to Boost Moribund Pharma Sector?

The global pharma and biotech sector has underperformed by about four points this year, and five over three years – the divergence with other...

Logo
219 Views
Share
bullishS&P 500 INDEX
06 Sep 2017 23:22

U.S. Equity Strategy: Reiterating Biotechs, Gold Miners; Downgrading Financials to Market Weight

Key themes: Downgrading Financials. Given the Sector’s relative deterioration, we are downgrading Financials to market weight. Pockets of strength...

Logo
483 Views
Share
x